Haddadin Yezan Munther

Haddadin Yezan Munther, Director, accounts for 3 disclosed filings worth $439.0K, all concentrated in Outlook Therapeutics, Inc. (OTLK), active 2025–2026. The record is heavily weighted toward buying, with $39.1K in purchases against $0 in sales. The largest single open-market purchase on record is $24.1K in Outlook Therapeutics, Inc.. Data is sourced from official SEC Form 3, 4, and 5 filings.